Douglas A Treco
CIK 1688192 · CEO & Chairman · last filed 2026-06-09
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.10M
Companies
3
Total Filings
23
Lifetime Open-Market Net
$1.08M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CRSP | Director | 22,000 | $49.80 | $1.10M | $1.14M | 8 | 2026-06-09 |
| Inozyme Pharma, Inc. (INZY) Delisted | CEO & Chairman | 43,861 | $4.00 | $175.4K | -$60.1K | 10 | 2025-06-27 |
| Ra Pharmaceuticals, Inc. (RARX) Delisted | President and CEO | 0 | — | — | $0 | 4 | 2020-04-03 |
Recent Filings · Page 3 of 3
23 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-02-05 | Ra Pharmaceuticals, Inc. (RARX) Delisted | Mixed | +14,507 | -$132.9K | EDGAR |
| 2018-02-05 | Ra Pharmaceuticals, Inc. (RARX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-02-03 | Ra Pharmaceuticals, Inc. (RARX) Delisted | Grant (A) | — | $0 | EDGAR |
Showing 21–23 of 23
Prev
Page 3 of 3
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.